每周泰索帝联合铂类方案治疗非小细胞肺癌的临床观察

Clinical Study of Weekly Docetaxel Combination With Cisplatin or Carboplatin in the Treatment of Advanced Non-small Cell Lung Cancer

目的 :评价泰索帝每周疗法联合铂类对晚期非小细胞肺癌的客观疗效及毒副反应。方法 :采用泰索帝每周 2 0 .2～ 2 9mg/m2 (中位剂量为每周 2 4 .4mg/m2 ) ,静脉滴入 ,连用 6周休 2周 ,并于第 1天、2 2天分别给予顺铂 6 0mg/m2 或卡铂 (AUC =5 )静脉滴入 ,所有患者均接受 8周以上的化疗。结果 :30例患者均可评价疗效 ,14例患者达到PR ,有效率为 4 6 .7%。中位生存期为 12个月 ,1年生存率为5 0 %。主要毒副反应为恶心呕吐和腹泻、肝功能损害、骨髓抑制、皮疹等。大部分患者为Ⅰ、Ⅱ度反应 ,患者耐受良好。经常规预防用药后 ,未观察到过敏反应、疲乏、浮肿现象。结论 :泰索帝每周疗法联合铂类方案是一种对晚期非小细胞肺癌有效的治疗方案 ,毒副反应轻 ,临床使用安全 。

Objective To evaluate the objective anti-cancer efficacy and safety of combination cisplatin or carbopolatin with docetaxel administered on a weekly basis for the advanced non-small cell lung cancer.Methods Thirty cases of advanced non-small cell lung cancer were administrated weekly docetaxel at median dose 24.4 mg/(m 2·wk),20.2-29 mg/(m 2·wk),each cycle consisted of 6 weeks of therapy followed by a 2-week treatment break,cisplatin 60 mg/m 2 or carboplatin(AUC=5)were given on d 1 and d 22 ,repeated every 8 weeks.All the patients received at least one cycle of the treatment.Results There were no complete responses.Fourteen patients had partial responses;the objective response rate was 46.7%.The median survival time was 12 months,one year survival rate was 50%.The major toxicity included nausea,vomiting and diarrhea,live function impaired,myelosuppression,and skin eruption.The severity of these side effects was mild to moderate and well tolerated.All patients were pretreated with dexamethasome,diphenhydramine and cimetidine.No severe hypersensitivity reaction was observed.no fluid retention and fatigue were observed.Conclusion Weekly docetaxel and platine or carboplatin combination regiment is active in treating patients with advanced non-small cell lung cancer,with mild to moderate side effect.Further clinical investigation should be warranted.